Mark Ranck, MD
Radiation Oncology · Fort Wayne, INNPI 1578710471
Payments from drug & device makers
What this record shows
25 manufacturers reported payments, led by AstraZeneca at 43.9% of the total. Reporting peaked in 2024 at $1,307 and has fallen 83.3% since, to $218 in 2025.
Across 52 payments — averaging $45.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novartis$181
- Boston Scientific$142
- Sumitomo Pharma America, Inc.$132
- E.r. Squibb & Sons, L.L.C.$121
- Eisai Inc.$120
- plus $645 from 19 others
What the payments were for
- Consulting fees$1,05044%
- Food & beverage$1,34156%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $1,050 |
| Novartis | 8 | $181 |
| Boston Scientific | 3 | $142 |
| Sumitomo Pharma America, Inc. | 7 | $132 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Eisai Inc. | 2 | $120 |
| Merck | 1 | $100 |
| Johnson & Johnson | 2 | $59 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $56 |
| Sanofi | 2 | $51 |
| Amgen | 3 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Myovant Sciences Inc. | 2 | $38 |
| Taiho Oncology, Inc. | 1 | $34 |
| Tersera Therapeutics LLC | 1 | $26 |
| Siemens Medical Solutions USA, Inc. | 1 | $26 |
| Lilly USA, LLC | 2 | $25 |
| Novocure Inc. | 1 | $23 |
| Fortovia Therapeutics, Inc. | 2 | $21 |
| Incyte Corporation | 1 | $20 |
| Sobi, Inc | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Dova Pharmaceuticals | 1 | $16 |
| Elekta, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,391 in reported general payments places this provider in the 80th percentile of 116 radiation oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 30 | $347 |
| Dexamethasone | 15 | $315 |
| Gabapentin | 12 | $121 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Fort Wayne
- Brian ChangFort Wayne$13K
- Zhigang YuanFort Wayne$1K
- Wesley RussellFort Wayne$1K
- Michael EatonIndianapolis$11K
- William PorterMadison$8K
- Binh TranMishawaka$7K
- Gordon WatsonIndianapolis$6K
- John CoxIndianapolis$5K
- Houman VaghefiGoshen$5K
- Peter GarrettIndianapolis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.